Internet Archive Scholar

Translational Safety Charts: Visualising the Safety Lifetime of Drugs from Preclinical Discovery to Postmarketing Surveillance
トランスレーショナル セーフティ チャート:前臨床から市販後調査までの医薬品安全性によるライフタイムの視覚化

Ricard GARCIA-SERNA, GARCIA-SERNA Ricard, Montserrat CASES, CASES Montserrat, Nikita REMEZ, REMEZ Nikita, Joaquim OLIVéS, OLIVéS Joaquim, Oriol LóPEZ-MASSAGUER, LóPEZ-MASSAGUER Oriol, Maria C CARRASCOSA, CARRASCOSA Maria C (+7 others)
2021

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (46.1 kB)
https://web.archive.org/web/20220823081845/https://www.jstage.jst.go.jp/article/toxpt/48.1/0/48.1_P-201/_pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Large amounts of data associated with safety issues are generated along the entire lifetime of drugs, from its infancy as preclinical leads, through its adolescence as clinical candidates, all the way up to its adulthood as marketed drugs exposed to the human population. Across the different stages in the life of a drug, some of the data collected initially may be confirmed and consolidated with data at an advanced stage, whereas other data may not be translated, and in some cases may even
more » ... adict, those safety signals that are ultimately observed in the human population. Collecting and properly integrating such an heterogenous pool of data is already a challenge in itself. But even if one manages to put all data together, the analysis is not straightforward, and it may require the assistance of purposely designed visual analytics tools. To this aim, we introduce the newly designed Translational Safety Charts that collect, in a single image, data from safety pharmacology, preclinical toxicology, clinical safety and postmarketing surveillance. They are implemented in CLARITY. PV, a new pharmacovigilance web-accessible platform that currently contains Translational Safety Charts for 8,060 drugs. A thoroughly validated methodology has been implemented to detect consolidated drug safety signals and link them to pharmacology, preclinical and clinical biomarkers. The analysis of safety signals can be extended beyond individual drugs to drug classes and stratified by age, weight, gender and geographical location.
doi:10.14869/toxpt.48.1.0_p-201 fatcat:vrvkmxvi7rbuldsu3ggqhp4nnu
lang:ja
Citation

Ricard GARCIA-SERNA, GARCIA-SERNA Ricard, Montserrat CASES, CASES Montserrat, Nikita REMEZ, REMEZ Nikita, Joaquim OLIVéS, OLIVéS Joaquim, Oriol LóPEZ-MASSAGUER, LóPEZ-MASSAGUER Oriol, Maria C CARRASCOSA, CARRASCOSA Maria C, Antonino LATTENE, LATTENE Antonino, Elisabet GREGORI-PUIGJANé, GREGORI-PUIGJANé Elisabet, Jordi MESTRES, MESTRES Jordi, Atsushi MIDORIKAWA. "Translational Safety Charts: Visualising the Safety Lifetime of Drugs from Preclinical Discovery to Postmarketing Surveillance." (2021) P-201